Royalty Report: Cancer, Medical, cell therapy – Collection: 324365


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 6


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 6

Primary Industries

  • Cancer
  • Medical
  • cell therapy
  • Drugs
  • Stem cells
  • Device

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 324365

License Grant
According to the agreement, the Licensees U.S. Subsidiary was granted a worldwide, royalty bearing, exclusive license from the Israeli Licensor, an affiliate of university,  to develop and commercialize technology directed to RAFT modification of polysaccharides and use of a bioreactor for supporting cell constructs.
License Property
Bioreactors and polysaccharides are part of the Cell & Gene Therapy Platform.

Bioreactors is for cell culture.

Polysaccharides is part of the Scaffold group. Scaffolds, including alginate and sulfated alginate scaffolds, polysaccharides thereof, and scaffolds for use for cell propagation, trans-differentiation, and transplantation in the treatment of autoimmune diseases.

Field of Use
The field of use is for the treatment of autoimmune diseases and to identify the most promising new autologous therapies and provide a pathway for them to reach patients more quickly, more efficiently and in a scalable way, thereby unlocking the power of cell and gene therapy for all patients. A wide range of therapies and supporting technologies include, but not limited to, Tumor Infiltrating Lymphocytes (“TILs”), CAR-T and CAR-NK, dendritic cell technologies, exosomes and bioxomes and viral vectors.

RUXIENCE is approved in the US for treating chronic Lymphotic leukemia, non-Hodgkin’s lymphoma, Microscopic Polyangiitis with glucocorticoids, and Granulomatosis with Polyangiitis.

Microscopic polyangiitis (MPA) is a condition that causes small blood vessels to be inflamed. It's a rare type of vasculitis. The disease can damage the blood vessels and cause problems in organs around the body. MPA most often affects people in their 50s and 60s, but it can happen in people of any age.

Granulomatosis with polyangiitis is an uncommon disorder that causes inflammation of the blood vessels in your nose, sinuses, throat, lungs and kidneys. Formerly called Wegener's granulomatosis, this condition is one of a group of blood vessel disorders called vasculitis. It slows blood flow to some of your organs.

IPSCIO Record ID: 323411

License Grant
Pursuant to a spin-off in 2016, Licensor acquired rights relating to Ruxience (rituximab).
License Property
Ruxience® is a mAb biosimilar to Rituxan which works by targeting a protein called CD20, which is present on the surface of B cells. When it attaches to CD20, rituximab helps destroy the B cells.
Field of Use
Ruxience is used in treatment for Non-Hodgkin’s Lymphoma (NHL) alone or with other chemotherapy medicines; Chronic Lymphocytic Leukemia (CLL) with the chemotherapy medicines fludarabine and cyclophosphamide; Granulomatosis with Polyangiitis (GPA) (Wegener’s Granulomatosis) and Microscopic Polyangiitis (MPA) with glucocorticoids.

Granulomatosis with polyangiitis is an uncommon disorder that causes inflammation of the blood vessels in your nose, sinuses, throat, lungs and kidneys. Formerly called Wegener's granulomatosis, this condition is one of a group of blood vessel disorders called vasculitis. It slows blood flow to some of your organs.

IPSCIO Record ID: 346226

License Grant
University granted us an exclusive, worldwide license under such patents and a nonexclusive royalty-bearing, worldwide license for such know-how to research, develop, commercialize and manufacture FCR001 and products containing FCR001 in all fields, without limitation. University also granted us the right to grant sublicenses in accordance with the University License Agreement.
License Property
The rights granted relate to certain licensed patent rights and know-how related to human facilitating cells for the Facilitated Allo-HSCT Therapy.

Aallogeneic hematopoietic stem cell transplantation (allo-HSCT), called Facilitated Allo-HSCT Therapy.  

The product candidate, FCR001, which is central to Facilitated Allo-HSCT Therapy, is a novel allogeneic cell therapy comprised of stem and immune cells that are procured from a healthy donor, who is also the organ donor in the case of organ transplantation. FCR001 is rapidly processed in the GMP facility using proprietary manufacturing methods. Then, at the time of the transplant, FCR001 is administered to the recipient following nonmyeloablative conditioning, which is designed to be less toxic than myeloablative conditioning. A fully myeloablative conditioning regimen consists of a combination of agents and high doses of total body irradiation that destroy hematopoietic stem cells (HSCs) in the bone marrow and results in profound depletion of HSC-derived cells within one to three weeks following administration that is irreversible, and in most instances is fatal unless rescued by a stem cell transplant. The nonmyeloablative conditioning for FCR001 entails lower doses of chemotherapy and total body irradiation, causes less depletion of blood cells and does not require stem cell support for the recipient to resume the production of blood cells and platelets.

Allo-HSCT Therapy has the potential to treat a range of severe autoimmune diseases and severe non-malignant blood, immune and metabolic disorders, in each case with potential for similar outcomes to what has previously been observed with HSCT, while mitigating the toxicities, morbidities and extended hospital stay associated with the conditioning regimen typically required by HSCT.

Field of Use
Field of use is for to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases and certain severe non-malignant blood, immune and metabolic disorders, in all fields, without limitation.

Facilitated Allo-HSCT Therapy could prevent organ rejection without the morbidity and mortality that has been associated with the use of lifelong anti-rejection medicines, also known as chronic immunosuppression.

IPSCIO Record ID: 336552

License Grant
Licensor of United Kingdom, whose key founders are also shareholders of the Licensee, pursuant to which the Licensee obtained a worldwide license to Licensor’s proprietary technology, know-how and intellectual property for the research, development and manufacture of TIL therapies obtained from tumors using Licensor’s technology.
License Property
TIL are tumor infiltrating lymphocyte therapies.

Tumor-infiltrating lymphocytes are white blood cells that have left the bloodstream and migrated towards a tumor. They include T cells and B cells and are part of the larger category of ‘tumor-infiltrating immune cells’ which consist of both mononuclear and polymorphonuclear immune cells, (i.e., T cells, B cells, natural killer cells, macrophages, neutrophils, dendritic cells, mast cells, eosinophils, basophils, etc.) in variable proportions. Their abundance varies with tumor type and stage and in some cases relates to disease prognosis

Field of Use
Tumor infiltrating lymphocyte or TIL is therapies for the treatment of patients with cancer.

IPSCIO Record ID: 356974

License Grant
Licensor, two individuals from Italy, grants an exclusive, perpetual and irrevocable license to make, use, have made, sell, offer to sell, import, manufacture, market and distribute the Licensed Technology within the Territory. Licensee shall appoint an exclusive distributor of the Licensed Technology in Italy at the conditions to be separately agreed between the parties.
License Property
Licensor is the inventor of certain processes and devices that allow for the migration of organic cells into tissue samples while being incubated in a specialized bioreactor, the Technology.

lmprovements mean any Intellectual Property developed after the Effective Date by the Inventor/Licensor or any third party affiliated with Licensor that constitutes an improvement or enhancement of the functions of the Technology, that is associated to the Technology and that relates to a bioreactor device able to feed and repopulate a rotating tubular structure, with the exclusion of different or new functions relating to generation of electrical fields, pressure fields and fluid dynamic fields.

Field of Use
The intellectual property rights relates to our InBreath Bioreactor.

This bioreactor is the first in a series of products that Licensee is developing to address what we believe is a long-term growth opportunity in the emerging field of regenerative medicine. Regenerative medicine is a new field that uses stem cells to repair damaged organs (e.g., spinal cord and heart) and also to grow tissue (e.g., bladder and bronchus) and organs (e.g., heart and lung) outside the body for transplant.

InBreath hollow organ bioreactor is a device that can be used by a surgeon to seed cells onto a scaffold. The InBreath bioreactor enables the surgeon to
secure the scaffold to the bioreactor;
seed the patient’s cells on the scaffold under sterile conditions;
automatically rotate the scaffold to allow good cell distribution into the pores of the scaffold; and
remotely monitor the scaffold during the course of the two to three days incubation period before the transplant.
The InBreath bioreactor has several novel features such as allowing for separate cell seeding conditions on the inside and outside of the scaffold and for pumping cell culture media through the inside of the scaffold without the need for an external pump and tubes. The Licensee believe the InBreath hollow organ bioreactor is the world’s first bioreactor that has been used to perform a human transplant of a regenerated organ.

The Technology has proven beneficial medical uses in organ transplant as well as the potential for use in other areas.

IPSCIO Record ID: 305481

License Grant
Licensor grants a sole and exclusive worldwide license or sublicense, as applicable, to the Licensor Technology for the CPS in the Field.
License Property
The patents include  Apparatus and Method for Maintaining  and Growing Biological Cells;  Methods of Increasing Rates of !n!ection by Directing Motion of Vectors;  Methods, Compositions and Apparatus for Cell Transfection; and, Methods, Compositions and Devices for Maintaining and Growing Human Stem and/or Hematopoietic Cells.

CPS means any system or device for substantially increasing, the number of cells, ex vivo, for human therapeutic uses, that may be configured in different component structures (such as described for the Automated CPS or the Manual CPS).

Licensed Product means the Automated CPS (both the Durables and the Disposables) as used for one or more specific Lymphoid Cell Applications.

Licensor is developing proprietary process technologies and devices for a range of cell therapy applications, including stem cell therapies and gene therapy. The lead product under development, the Licensors Cell Production System (the CPS) consists of a clinical cell culture system with disposable cassettes and reagents for use in the rapidly growing stem cell therapy market.

Field of Use
Field means Lymphoid Cell Applications.  Application means (a) the expansion of any Lymphoid Cell for one or more therapeutic uses, or (b) the transfection of a specific Lymphoid Cell type modified with a naturally occurring gene or a synthetic modification thereof for a specific therapeutic use. One Application is tumor infiltrating lymphocytes (TIL), such that TIL therapy for renal cell carcinoma and TIL therapy for breast cancer are part of the same Application.

Licensee, a competitor, along with others, are in advanced stages of development of technologies and products for use in stem cell therapy and other market applications currently being pursued by the Licensor.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.